At Kuno Creative, our mission is to help companies we believe in get results. This is the ninth in a series featuring our clients, their mission and how they’re pivoting their marketing strategy in the midst of the coronavirus pandemic.
Imagine you visit a loved one, only to discover them lying on the floor, unable to move. They have aphasia and weakness on their right side. You suspect a stroke and call 911. You arrive at the hospital, and they ask when your loved one had last been seen well. You are not sure.
The hospital informs you there is no treatment that can be applied since the “golden window”— the roughly six-hour period following a stroke where treatment is effective without risking bleeding in the brain — has passed.
Dr. Greg Albers, co-founder of RapidAI, was never satisfied with this thinking. He believed stroke evolution was highly variable and realized technology was the limiting factor. He and co-founder Roland Bammer worked to develop what is the most advanced cerebrovascular imaging platform available to hospitals today.
Here’s a look at how RapidAI is working to help patients during COVID-19 and every day.
Stroke is a leading cause of serious long-term disability. Additionally, someone in the United States has a stroke every 40 seconds, and every 4 minutes, someone dies of a stroke, according to the Centers for Disease Control and Prevention.
The artificial intelligence-based RapidAI® platform empowers clinicians to make faster, more accurate treatment decisions for stroke patients. Speed is imperative because the faster a stroke patient gets the proper treatment, the better his or her outcome is likely to be. Delays increase the extent of brain damage in most cases. The platform also allows physicians to treat qualified patients outside the “golden window,” saving more lives and improving more lives.
RapidAI has been studied and validated in 14 clinical studies worldwide, making it the gold standard for advanced cerebrovascular imaging.
See RapidAI in Action
The truth is, we still don’t know that much about COVID-19. What are the symptoms? Will it mutate? Can you get it again if you’ve already had it once?
The story that made this lack of information clearest was published in The Washington Post on April 25. Essentially, otherwise healthy people in their 30s and 40s were having strokes. The common factor: they were all infected with coronavirus.
“The analyses suggest coronavirus patients are mostly experiencing the deadliest type of stroke. Known as large vessel occlusions, or LVOs, they can obliterate large parts of the brain responsible for movement, speech and decision-making in one blow because they are in the main blood-supplying arteries.”
Hospitals with access to RapidAI were able to make faster and more-informed triage decisions for COVID-19 patients experiencing stroke symptoms.
At Kuno, we make it a point to work with companies we believe are making the world a better place. RapidAI is a clear example of this mission, and we are honored to be working with them to rebrand their company and website, and launch brand awareness campaigns.
Our hope is that RapidAI will be in every hospital around the world, so no stroke victim is limited in their treatment options. We are grateful that we can help RapidAI on their mission to empower clinicians to make faster, more accurate diagnostic and treatment decisions for stroke patients — improving patient care and outcomes every day.
